Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The article in the April 24 edition of JACC concluded that the shorter procedure time and lower bailout rate of the TAXUS Liberte Stent system compared to the TAXUS(R) Express2(TM) Stent system may represent a clinical surrogate for the improved deliverability and conformability of the TAXUS Liberte Stent as compared to the TAXUS Express Stent.

TAXUS ATLAS is a global, multi-center single arm trial comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies that received the TAXUS Express2 paclitaxel-eluting stent system. Even with more complex lesion characteristics(2) compared to the control group, the TAXUS ATLAS trial met its primary endpoint of nine-month target vessel revascularization (TVR) non-inferiority.

The TAXUS ATLAS nine-month results also support safety, as demonstrated by low rates of Major Adverse Cardiac Events (MACE) and stent thrombosis. The MACE rate and its components, including cardiac death, myocardial infarction and TVR, were comparable to control despite the higher percentage of complex lesions for the TAXUS Liberte Stent arm. Cardiac death for the control group was 0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent (p=1.00). Myocardial infarction was 3.9 percent for the control group compared to 3.7 percent for the TAXUS Liberte Stent (p=0.9030). The nine-month TVR rate for the control group was 7.1 percent compared to 8.0 percent for the TAXUS Liberte Stent (p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte Stent group, as compared to 8.9 perc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... 2014   Vestagen Technical Textiles, Inc. today ... hospitals. The myComfort™ line of patient apparel is protected ... is fluid repellant, breathable and in studies done in ... bacteria on the fabric i . "It,s ... chain of transmission. We want myComfort to be a ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
Breaking Medicine Technology:Global Laparoscopy Devices Industry Report 2014 2New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
(Date:9/16/2014)... 16, 2014 Paradigm Physical Therapy is ... new therapeutic treatment for their patients. Dry needling is ... a variety of musculoskeletal problems. , In this invasive ... into the skin and muscle to create a trigger ... the needle helps to deactivate and release the trigger ...
(Date:9/16/2014)... Wearable electronic activity monitors hold great promise in ... goals. These increasingly sophisticated devices help the wearers ... and bodily responses. This information is organized into ... Given the large and quickly growing market for ... Medical Branch at Galveston analyzed 13 of these ...
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... September 16, 2014 Seven heroes who ... world will be honored in New York City on ... ), the only global recognition and funding program that ... by the media as the “Nobel Prize for Child ... created life-changing programs that benefit children in countries around ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... the first objective scientific way to diagnose major depression in ... levels of nine genetic indicators (known as "RNA markers") in ... respond to cognitive behavioral therapy, one of the most common ... therapy worked, Northwestern University researchers report. Depression affects nearly ...
Breaking Medicine News(10 mins):Health News:Paradigm Physical Therapy Introduces Dry Needling 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... ... not friendly one-on-one conversation. , ... New York, NY (PRWEB) November 18, 2009 -- A new national ... e-patients to “friend” them on Facebook. Instead, health organizations would be better off ...
... Young football ... sustain a series of even small head bumps may be at increased risk of long-term brain ... Boston (Vocus) November 19, 2009 ... But players who sustain a series of even small head bumps may be at increased risk ...
... Plavix bested by latest anti-clotting alternatives , WEDNESDAY, Nov. ... three new trials suggest that the latest generation of ... clopidogrel (Plavix). , In one study, dabigatran etexilate (marketed ... is not yet approved in the United States) proved ...
... Preliminary report from the Harvard School of Public Health reveals students ... Think your kids won,t eat healthy foods? Think again. A preliminary ... of Public Health, funded by Project Bread, proves that kids not ... healthy foods than they would if they were eating a traditional ...
... Calif., Nov. 18 Endologix, Inc. (Nasdaq: ... aortic disorders, announced today that it has received ... United States Food and Drug Administration ("FDA") to ... a bilateral percutaneous approach to endovascular abdominal aortic ...
... announces the November 2009 publication of a special ... devoted to residential design for persons with neurodisability. ... of the long-term living environment can improve quality ... who are cognitively, behaviorally and/or physically challenged due ...
Cached Medicine News:Health News:Older E-Patients Prefer Facts, Not Friendship from Health Organizations Communicating Via Social Media, According to Path of the Blue Eye Project Survey 2Health News:Throw a Yellow Flag on Football-related Head Injuries, Warns the Harvard Mental Health Letter 2Health News:Newer Blood Thinners May Outperform Old Standbys 2Health News:Newer Blood Thinners May Outperform Old Standbys 3Health News:New Study Proves Kids Like Eating Healthy Food 2Health News:New Study Proves Kids Like Eating Healthy Food 3Health News:Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR 2Health News:Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR 3Health News:Residential design for persons with neurological disability 2Health News:Residential design for persons with neurological disability 3
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
... wide variety of applications. • Whole pipette is ... freely rotated against the handle to work in ... angle towards the microtiter plate. • The special ... common pipette tips, and provides a firm, parallel ...
... with 96-well plates in mind, Pipetman ... molecular biology applications: PCR* sequencing, immunology ... etc. Used with Diamond Tips from ... product will maximize performance and assure ...
... Multichannel, with it's streamlined design, ... routine laboratory tasks. The multichannel ... Soft-touch tip ejection, Super blow-out ... models), Entire pipette autoclavable, streamlined ...
Medicine Products: